Tumors either got smaller or stopped growing in more than two-fifths of certain advanced urothelial cancer patients put on an experimental drug from Seattle Genetics, according to clinical trial data presented Monday at the American Society of Clinical Oncology's annual meeting.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,